<DOC>
	<DOCNO>NCT01059552</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose combination vorinostat , cisplatin , pemetrexed , radiation therapy patient unresectable stage IIIA/IIIB non-small cell lung cancer .</brief_summary>
	<brief_title>Treatment Locally Advanced Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>This phase I trial escalate dose histone deacetylase inhibitor ( HDAC ) vorinostat chemoradiation platform cisplatin , pemetrexed radiation dose 70Gy NSCLC patient unresectable IIIA dry IIIB disease . The endpoint determine MTD combination .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>biopsy proven nonsquamous NSCLC unresectable stage IIIA dry IIIB disease . FEV1 &gt; /= 1 liter ECOG PS 0 1 Able swallow absorb enterally Measurable disease per RECIST 1.1 Adequate organ marrow function include calculated creatinine clearance &gt; /= 60 mL/min hepatic enzyme alk phos &lt; /= 2.5 X ULN . Chemotherapy radiotherapy &lt; /= 4 week prior registration ( 6 week nitrosureas ) Active bleed Known brain mets Prior thoracic radiotherapy would lead overlap current radiation field . More 10 % weight loss 6 month . Pancoast tumor , supraclavicular contralateral hilar lymph node involvement Known HIV positive Prior treatment HDAC inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>lung cancer</keyword>
	<keyword>locally advanced lung cancer</keyword>
</DOC>